Rating Change
Goldman Sachs analysts upgraded Protagonist Therapeutics, Inc. (NASDAQ:PTGX) from Neutral to Buy on August 10, 2026.
upgradeNASDAQ:PTGX
Protagonist Therapeutics, Inc. (PTGX) Upgraded to Buy at Goldman Sachs
Goldman Sachs analysts upgraded Protagonist Therapeutics, Inc. (NASDAQ:PTGX) from Neutral to Buy on August 10, 2026.
At publication ·
What changed
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) · upgrade
- Firm
- Goldman Sachs
- Rating
- Neutral to Buy
- Price at event
- $150.00
- Market capitalization
- $5.8B
At a glance
Key takeaways
- Goldman Sachs upgraded Protagonist Therapeutics (PTGX) from Neutral to Buy on August 10, 2026, suggesting analysts see improving fundamentals or favorable risk-reward dynamics.
Market Context
Protagonist Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $150.00 with a market capitalization of $5.8B.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Goldman Sachs's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Protagonist Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | Wedbush | Outperform | N/A |
| Aug 10, 2026 | Truist Securities | Buy | N/A |
| Aug 10, 2026 | Goldman Sachs | Buy | N/A |
| Aug 06, 2026 | Barclays | Overweight | N/A |
| Aug 06, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PTGX Stock Page
Frequently Asked Questions
What does the Buy rating mean for PTGX?
A rating of Buy from Goldman Sachs reflects the analyst's outlook on Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PTGX forecast page.